291 related articles for article (PubMed ID: 28970500)
21. Activation of farnesoid X receptor increases the expression of cytokine inducible SH2-containing protein in HepG2 cells.
Xu Z; Huang G; Gong W; Zhao Y; Zhou P; Zeng Y; He F
J Interferon Cytokine Res; 2012 Nov; 32(11):517-23. PubMed ID: 22817871
[TBL] [Abstract][Full Text] [Related]
22. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration.
Li YT; Swales KE; Thomas GJ; Warner TD; Bishop-Bailey D
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2606-11. PubMed ID: 18029909
[TBL] [Abstract][Full Text] [Related]
23. Obeticholic Acid Protects against Lipopolysaccharide-Induced Fetal Death and Intrauterine Growth Restriction through Its Anti-Inflammatory Activity.
Chen YH; Hu XG; Zhou Y; Yu Z; Fu L; Zhang GB; Bo QL; Wang H; Zhang C; Xu DX
J Immunol; 2016 Dec; 197(12):4762-4770. PubMed ID: 27821667
[TBL] [Abstract][Full Text] [Related]
24. Glycochenodeoxycholate promotes the metastasis of gallbladder cancer cells by inducing epithelial to mesenchymal transition via activation of SOCS3/JAK2/STAT3 signaling pathway.
Wang H; Zhan M; Liu Q; Wang J
J Cell Physiol; 2020 Feb; 235(2):1615-1623. PubMed ID: 31347168
[TBL] [Abstract][Full Text] [Related]
25. SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway.
Chen M; Zeng J; Chen S; Li J; Wu H; Dong X; Lei Y; Zhi X; Yao L
Aging (Albany NY); 2020 Jun; 12(11):10896-10911. PubMed ID: 32516133
[TBL] [Abstract][Full Text] [Related]
26. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
[TBL] [Abstract][Full Text] [Related]
27. Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice.
Li G; Kong B; Zhu Y; Zhan L; Williams JA; Tawfik O; Kassel KM; Luyendyk JP; Wang L; Guo GL
Toxicol Appl Pharmacol; 2013 Oct; 272(2):299-305. PubMed ID: 23811326
[TBL] [Abstract][Full Text] [Related]
28. The roles of SOCS3 and STAT3 in bacterial infection and inflammatory diseases.
Gao Y; Zhao H; Wang P; Wang J; Zou L
Scand J Immunol; 2018 Dec; 88(6):e12727. PubMed ID: 30341772
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of STAT3 signaling pathway by ursolic acid suppresses growth of hepatocellular carcinoma.
Liu T; Ma H; Shi W; Duan J; Wang Y; Zhang C; Li C; Lin J; Li S; Lv J; Lin L
Int J Oncol; 2017 Aug; 51(2):555-562. PubMed ID: 28714512
[TBL] [Abstract][Full Text] [Related]
30. Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand.
Yu J; Yang K; Zheng J; Zhao W; Sun X
Cancer Gene Ther; 2021 Jun; 28(6):590-601. PubMed ID: 33046820
[TBL] [Abstract][Full Text] [Related]
31. FXR ligands protect against hepatocellular inflammation via SOCS3 induction.
Xu Z; Huang G; Gong W; Zhou P; Zhao Y; Zhang Y; Zeng Y; Gao M; Pan Z; He F
Cell Signal; 2012 Aug; 24(8):1658-64. PubMed ID: 22560881
[TBL] [Abstract][Full Text] [Related]
32. 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol negatively regulates activation of STAT3 and ERK pathways and exhibits anti-cancer effects in HepG2 cells.
Ai HH; Zhou ZL; Sun LG; Yang MT; Li W; Yu CL; Song ZB; Huang YX; Wu Y; Liu L; Yang XG; Zhao YQ; Bao YL; Li YX
Apoptosis; 2017 Nov; 22(11):1404-1418. PubMed ID: 28864870
[TBL] [Abstract][Full Text] [Related]
33. JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway.
Fang J; Chu L; Li C; Chen Y; Hu F; Zhang X; Zhao H; Liu Z; Xu Q
Oncol Rep; 2015 Jan; 33(1):494-502. PubMed ID: 25405520
[TBL] [Abstract][Full Text] [Related]
34. Paeoniflorin suppresses IL-6/Stat3 pathway via upregulation of Socs3 in dendritic cells in response to 1-chloro-2,4-dinitrobenze.
Shi D; Wang Q; Zheng H; Li D; Shen Y; Fu H; Li T; Mei H; Lu G; Qiu Y; Chen G; Liu W
Int Immunopharmacol; 2016 Sep; 38():45-53. PubMed ID: 27236299
[TBL] [Abstract][Full Text] [Related]
35. Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms.
Guo C; LaCerte C; Edwards JE; Brouwer KR; Brouwer KLR
J Pharmacol Exp Ther; 2018 May; 365(2):413-421. PubMed ID: 29487110
[TBL] [Abstract][Full Text] [Related]
36. Long non-coding RNA FEZF1-AS1 promotes cell invasion and epithelial-mesenchymal transition through JAK2/STAT3 signaling pathway in human hepatocellular carcinoma.
Wang YD; Sun XJ; Yin JJ; Yin M; Wang W; Nie ZQ; Xu J
Biomed Pharmacother; 2018 Oct; 106():134-141. PubMed ID: 29957463
[TBL] [Abstract][Full Text] [Related]
37. Obeticholic acid alleviate lipopolysaccharide-induced acute lung injury via its anti-inflammatory effects in mice.
Fei J; Fu L; Hu B; Chen YH; Zhao H; Xu DX; Li JB
Int Immunopharmacol; 2019 Jan; 66():177-184. PubMed ID: 30468885
[TBL] [Abstract][Full Text] [Related]
38. Correlation of IL-6 and JAK2/STAT3 signaling pathway with prognosis of nasopharyngeal carcinoma patients.
Zhuang M; Ding X; Song W; Chen H; Guan H; Yu Y; Zhang Z; Dong X
Aging (Albany NY); 2021 Jun; 13(12):16667-16683. PubMed ID: 34165442
[TBL] [Abstract][Full Text] [Related]
39. Zerumbone inhibits growth of hormone refractory prostate cancer cells by inhibiting JAK2/STAT3 pathway and increases paclitaxel sensitivity.
Jorvig JE; Chakraborty A
Anticancer Drugs; 2015 Feb; 26(2):160-6. PubMed ID: 25243457
[TBL] [Abstract][Full Text] [Related]
40. Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1.
Ahn KS; Sethi G; Sung B; Goel A; Ralhan R; Aggarwal BB
Cancer Res; 2008 Jun; 68(11):4406-15. PubMed ID: 18519703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
